Verapamil Reverses Myocardial No-Reflow After Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction

Cell Biochemistry and Biophysics

Volumn 67, Issue 3, 2013, Pages 911-914

  Fu, Qiang ^a   Lu, Wen ^a   Huang, Yi jie ^a   Wu, Qiang ^a   Wang, Lin guang ^a   Wang, Hai bo ^a   Jiang, Shu zhong ^a   Wang, Yan jiong ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Angioplasty; Myocardial infarction; No reflow; Stents; Verapamil

Indexed keywords

ATROPINE; VASODILATOR AGENT; VERAPAMIL;

ACUTE DISEASE; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BRADYCARDIA; FEMALE; HEART INFARCTION; HUMAN; HYPOTENSION; INCIDENCE; MALE; MIDDLE AGED; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; STENT; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ATROPINE; BRADYCARDIA; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; HYPOTENSION; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME; VASODILATOR AGENTS; VERAPAMIL;

EID: 84888350699     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9581-0     Document Type: Article

References (19)

1. Isaaz, K., Robin, C., Cerisier, A., Lamaud, M., Richard, L., Da, C. A., et al. (2006). A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coronary Artery Disease, 17, 261-269.
2. Rezkalla, S. H., Dharmashankar, K. C., Abdalrahman, I. B., & Kloner, R. A. (2010). No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. Journal of Interventional Cardiology, 23, 429-436.
3. Lee, C. H., Wong, H. B., Tan, H. C., Zhang, J. J., Teo, S. G., Ong, H. Y., et al. (2005). Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1, 328 patient registry. Journal of Interventional Cardiology, 18, 261-266.
4. Rezkalla, S. H., & Kloner, R. A. (2008). Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheterization & Cardiovascular Interventions, 72, 950-957.
5. Chesebro, J. H., Knatterud, G., Roberts, R., Borer, J., Cohen, L. S., Dalen, J., et al. (1987). Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation, 76, 142-154.
6. Kloner, R. A., Ganote, C. E., & Jennings, R. B. (1974). The "no-reflow" phenomenon after temporary coronary occlusion in the dog. The Journal of Clinical Investigation, 54, 1496-1508.
7. Ito, H., & Iwakura, K. (1998). Assessing the relation between coronary reflow and myocardial reflow. American Journal of Cardiology, 81, 8G-12G.
8. Villanueva, F. S. (2002). Myocardial contrast echocardiography in acute myocardial infarction. American Journal of Cardiology, 2002(90), 38J-47J.
9. Nakamura, S., Takehana, K., Sugiura, T., Hatada, K., Hamada, S., Asada, J., et al. (2003). Quantitative estimation of myocardial salvage after primary percutaneous transluminal coronary angioplasty in patients with angiographic no reflow. The European Journal of Nuclear Medicine and Molecular Imaging, 30, 383-389.
10. Mehta, R. H., Harjai, K. J., Boura, J., Cox, D., Stone, G. W., O'Neill, W., et al. (2003). Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. American Journal of Cardiology, 92, 1445-1447.
11. Reffelmann, T., Hale, S. L., Dow, J. S., & Kloner, R. A. (2003). No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation, 108, 2911-2917.
12. Demir, I., Yilmaz, H., Ermis, C., & Sancaktar, O. (2002). Treatment of no-reflow phenomenon with verapamil after primary stent deployment during myocardial infarction. Japanese Heart Journal, 43, 573-580.
13. Resnic, F. S., Wainstein, M., Lee, M. K., Behrendt, D., Wainstein, R. V., Ohno-Machado, L., et al. (2003). No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. American Heart Journal, 145, 42-46.
14. Bolognese, L., Falsini, G., Liistro, F., Angioli, P., & Ducci, K. (2005). Epicardial and microvascular reperfusion with primary percutaneous coronary intervention. Italian Heart Journal, 6, 447-452.
15. Reffelmann, T., & Kloner, R. A. (2004). Effects of adenosine and verapamil on anatomic no-reflow in a rabbit model of coronary artery occlusion and reperfusion. Journal of Cardiovascular Pharmacology, 43, 580-588.
16. Werner, G. S., Lang, K., Kuehnert, H., & Figulla, H. R. (2002). Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheterization & Cardiovascular Interventions, 57, 444-451.
17. Umemura, S., Nakamura, S., Sugiura, T., Tsuka, Y., Fujitaka, K., Yoshida, S., et al. (2006). The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention. Nuclear Medicine Communications, 27, 247-254.
18. Alfayoumi, F., Srinivasan, V., Geller, M., & Gradman, A. (2005). The no-reflow phenomenon: epidemiology, pathophysiology, and therapeutic approach. Reviews in Cardiovascular Medicine, 6, 72-83.
19. Morishima, I., Sone, T., Okumura, K., Tsuboi, H., Kondo, J., Mukawa, H., et al. (2000). Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. Journal of the American College of Cardiology, 36, 1202-1209.